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Abstract
Background: Effective vaccines to combat malaria are urgently needed, but have proved elusive in the absence of validated
correlates of natural immunity. Repeated blood stage infections induce antibodies considered to be the main arbiters of
protection from pathology, but their essential functions have remained speculative.
Methodology/Principal Findings: This study evaluated antibody dependent respiratory burst (ADRB) activity in
polymorphonuclear neutrophils (PMN) induced by Plasmodium falciparum merozoites and antibodies in the sera of two
different African endemic populations, and investigated its association with naturally acquired clinical protection.
Respiratory bursts by freshly isolated PMN were quantified by chemiluminescence readout in the presence of isoluminol,
which preferentially detects extra-cellular reactive oxygen species (ROS). Using a standardized, high throughput protocol,
230 sera were analyzed from individuals of all age groups living in meso- (Ndiop) or holo-endemic (Dielmo) Senegalese
villages, and enrolled in a cross-sectional prospective study with intensive follow-up. Statistical significance was determined
using non-parametric tests and Poisson regression models. The most important finding was that PMN ADRB activity was
correlated with acquired clinical protection from malaria in both high and low transmission areas (P=0.006 and 0.036
respectively). Strikingly, individuals in Dielmo with dichotomized high ADRB indexes were seventeen fold less susceptible to
malaria attacks (P=0.006). Complementary results showed that ADRB activity was (i) dependent on intact merozoites and
IgG opsonins, but not parasitized erythrocytes, or complement, (ii) correlated with merozoite specific cytophilic IgG1 and
IgG3 antibody titers (P,0.001 for both), and (iii) stronger in antisera from a holo-endemic compared to a meso-endemic site
(P=0.002), and reduced in asymptomatic carriers (P,0.001).
Conclusions/Significance: This work presents the first clearly demonstrated functional antibody immune correlate of
clinical protection from Plasmodium falciparum malaria, and begs the question regarding the importance of ADRB by PMN
for immune protection against malaria in vivo.
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Introduction
There are 300–500 million clinical malaria cases annually, and
1–3 million deaths of primarily young African children [1]. Blood
stage Plasmodium falciparum causes the most morbidity and mortality,
and widespread multi-drug resistance has accentuated the need for
an effective vaccine. Merozoite surface proteins (MSPs) are
considered relevant vaccine targets, because they mediate erythro-
cyte invasion, and are accessible to antibodies and complement.
Indeed, high IgG antibody titers to some MSP recombinant
antigens have been correlated with acquired immunity in endemic
populations [2–5]. One postulated antibody function is to inhibit
parasite growth by preventing erythrocyte invasion and/or by
interfering with intra-erythrocytic development. The currently most
widely accepted functional assays for antibodies to blood stage P.
falciparum antigens measure inhibition of erythrocyte invasion and/
or parasite growth in vitro [6–11], but the relevance of these assays to
clinical protection in humans has never been clearly established.
A second category of antibody activity concerns antibody
dependent cellular functions. Possible cellular immune effectors
for blood stage malaria include polymorphonuclear neutrophils
(PMN) and/or monocytes, since mature erythrocytes lack histo-
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vascular tissues. It has been proposed that monocytes activated by
opsonized merozoites, release an unidentified soluble factor that
inhibits the growth of surrounding intra-erythrocytic parasites. A
functional antibody assay is based on this notion (antibody
dependent cellular inhibition, ADCI) [6,12], but it has not been
widely reproduced in other laboratories, and the relevance of the
assay itself to clinical protection in humans has not been statistically
validated either in prospective longitudinal studies or otherwise.
Neutrophils are quite plausible immune effectors for the control
of Plasmodium blood stage infection because they are the most
numerous blood leucocytes (50–75%), and the best circulatory
phagocytes. Opsonized merozoites are known to be phagocytosed
by neutrophils in vitro [13,14] and in vivo [15]. In addition,
neutrophils are particularly effective generators of reactive oxygen
species (ROS), which are highly toxic for intra-erythrocytic
malaria parasites [12,16–18] and high ROS production by
neutrophils has been correlated with fast parasite clearance in
Gabonese children with P. falciparum malaria [19].
These observations suggested that ROS release by activated
neutrophils might be more involved in immune protection from
malaria than generally appreciated. Surprisingly, reviews of
immune effector mechanisms against blood stage Plasmodium
infection rarely mention or highlight roles for neutrophils or
ROS [20,21]. Neutrophil respiratory bursts can be quantified by
emitted light detected with chemiluminescence dyes [22–25], and
can be triggered by opsonized P. falciparum merozoites, and
enhanced by cytokines [26]. Large scale functional analysis of anti-
merozoite antibodies using this approach, has been limited by a
lack of miniaturized and/or automated procedures [13,26–28]. To
investigate relationships between neutrophil antibody dependent
respiratory burst (ADRB) activity and acquisition of natural
immunity to malaria, a reproducible, standardized, high through-
put in vitro chemiluminescence protocol was developed, based on
merozoites opsonized with antibodies in the sera of two P.
falciparum exposed populations. The results presented constitute the
first demonstration of a functional antibody correlate of clinical
protection against P. falciparum malaria. The ADRB assay could
help to reliably prioritize MSP vaccine candidates [8,29–31] for
clinical testing, and its surprising statistical correlations may focus
new attention on the in vivo relevance of the ADRB mechanism.
Materials and Methods
Study sites
Two villages in Senegal with different malaria epidemiology
were studied. In Dielmo malaria transmission is perennial because
a nearby river maintains continuous mosquito breeding sites. In
Ndiop, transmission is strictly seasonal and depends on the rainy
season that normally occurs from July to September. This differing
transmission is reflected in relatively constant P. falciparum
prevalence rates of .80% in Dielmo compared to seasonal rates
in Ndiop that change from 20% in the dry season to 70% in the
rainy season [32]. Consequently, the peak incidence of clinical
malaria in Dielmo occurs in very young children of 2–5 years and
declines rapidly with age, whereas in Ndiop peak incidence is in
children of 5–10 years with only a gradual decrease in age. A field
research station with a dispensary was built for the project in each
village to identify and treat all episodes of morbidity.
Subjects and ethics statement
The Dielmo and Ndiop longitudinal surveys have been described
in detail elsewhere [32,33]. The project protocol and objectives were
carefully explained to the assembled village population and informed
consent was individuallyobtained from all subjects either by signature
or by thumbprint on a voluntary consent form written in both French
and in Wolof, the local language. Such consent was obtained in the
presence of the school director, an independent witness. For very
young children, parents or designated tutors signed on their behalf.
The protocol and consent procedure was approved by the Ethical
Committee of the Institut Pasteur de Dakar and the Ministe ` r ed el a
Sante ´ of Senegal. An agreement between Institut Pasteur de Dakar,
Institut de Recherche pour le De ´veloppement (IRD) and the
Ministe ` r ed el aS a n t e ´e td el aP r e ´vention of Senegal defines all
research activities in Dielmo and Ndiop. Each year, the project was
re-examined by the Conseil de Perfectionnement de l’Institut Pasteur
de Dakar andtheassembled villagepopulation; informed consent was
individually renewed from all subjects.
In order to comprehensively identify all episodes of morbidity,
villagers were under constant daily medical surveillance. At least one
physician, a technician or a nurse, and three medical field workers
were present in the village 24 hr a day, seven days a week. Active
case detection was carried out such that each villager received daily
homevisits.For eachclinicalepisode with a historyoffever($38uC),
headache, or vomiting, thick blood films were made for treatment
decisions, and clinical symptoms were systematically recorded.
In July 2002, before the transmission season in Ndiop, villagers
from Ndiop (114) and Dielmo (116) were enrolled in a longitudinal
and cross-sectional study [32,34]. None were symptomatic for
malaria, but were not screened for circulating parasites (asymp-
tomatic malaria). The mean age of the Ndiop and Dielmo cohorts
was 24.0 (3.4–76.9) and 28.6 (3.4–80.5) years respectively. The
number of infective bites per person per day during the period just
preceding the beginning of the study was 0 and 1.97 for Ndiop and
Dielmo residents respectively. During the study period residents of
Ndiop and Dielmo received an average of around 20 or 295
infective bites per inhabitant respectively (Boudin et al., unpub-
lished data). After venous puncture, RBCs were removed by
centrifugation and plasma was stored at 220uC.
Antibodies
Sera were de-complemented by heating 20 min at 56uC. A
hyper-immune serum pool (HIS) from 30 adult residents of
Dielmo, and non-immune serum pool (NIS) obtained commer-
cially (Valbiotech, France), were the positive and negative controls
respectively. Total IgG was purified using UltralinkH immobilized
Protein-G (Pierce) according to the manufacturer’s instructions.
Briefly, sera (0.4 mL) were diluted 1:5 in binding buffer, passed 3
times over 2 mL of packed resin and washed with 15 column
volumes of binding buffer. IgG was eluted with 10 mL of elution
buffer, neutralized with 1M Tris pH 8.0, dialyzed against PBS,
and concentrated to 0.4 mL (Amicon Ultra, 5,000 MWCO;
Millipore). IgG-depleted sera were obtained by concentrating
flow-through fractions to the initial 0.4 mL volume.
High titer rabbit polyclonal anti-PfMSP1p19 antibodies raised
to purified baculovirus recombinant PfMSP1p19 [35], were used
to characterize merozoite preparations.
Parasite culture and merozoite preparation
Palo Alto (FCR3) P. falciparum was cultured continuously on O
+
erythrocytes in RPMI containing 0.5% Albumax and 1 mg.mL
21
gentamycin, in candle jars [36]. Merozoite extracts were prepared by
two methods. (i) Cultures with .5% parasitemia were centrifuged
5 min at 400xg. RBCs (pellet) were replaced in culture, and
merozoites in supernatants were recovered by centrifugation for
20 min at 1500xg and stored at 220uC in the RPMI/Albumax
culture medium. (ii) After synchronization using D-sorbitol, cultures
containing mature schizonts were centrifuged 10 min at 700xg at RT
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interface were washed once in PBS, while infected erythrocytes in the
pellet were washed in RPMI and replaced in culture. Merozoite
pellets were stored at 220uC with no additives and aliquots were
pooled as needed. Alternatively, sonicated merozoites, normal or
parasitized RBC, or freeze-thawed parasitized RBC pellets were used
for controls.
Effector cell preparation
Blood samples from healthy adults presenting for routine blood
tests at the Pasteur Institute, Dakar were obtained with informed
written consent approved by the Ethical Committee of the Institut
Pasteur de Dakar. Samples from 6–7 donors (4 mL each), were
collected into EDTA-K3 tubes, layered onto Ficoll-Hystopaque
(density 1.077, Sigma) and centrifuged at RT for 30 min at 400xg.
PMN were harvested at the ficoll-RBC interface. Residual RBCs
were lysed by incubation in 8.32 g.L
21 NH4Cl, 0.8 g.L
21 sodium
bicarbonate, and 0.043 g.L
21 EDTA 8 min at 4uC and centrifuged
at 400xg for 5 min. Purified effector cells were washed twice with
Hank’s balanced salt solution (HBSS), enumerated using trypan
blue, and resuspended in PBS at 1–5.10
7 cells mL
21, depending on
the quantity of PMN collected on a given day and the number of
wells tested. Within this concentration range there was no effect on
readout under the conditions of the assay. The major contaminants
were cellular debris and RBC. Viability (verified before every
experiment) was .99% and PMNs constituted 90–99% of
leucocytes. PMN were used immediately after harvest and
purification, usually within 2–3 hr following sample collection.
Chemiluminescence monitoring of ROS generation
Chemiluminescence was measured at 37uC using opaque 96-
well plates (Berthold), and a MicroLumat Plus 96 luminometer
(Berthold), controlled with WinGlow software. Chemilumines-
cence was recorded as relative light units (rlu). A 4 mg.mL
21 stock
solution of isoluminol (4-aminophthalhydrazide; Sigma) prepared
in DMSO, was stored in aliquots at –20uC in the dark, and used at
a final concentration of 0.04 mg.mL
21 in sterile PBS. To facilitate
rapid handling, only 40–50 wells per plate were used. Merozoite
pellets (40 mL), or alternatively normal or parasitized red cell
pellets, were incubated with 10 mL of test or control sera or IgG
for at least 30 min at 37uC. PMN (100 mL at 1–5.10
7 cells mL
21)
and isoluminol (100 mL) were loaded rapidly using an Eppendorf
Multipipette 4780. Plate reading started immediately, and each
well was monitored automatically by the luminometer for 1 sec
every minute for 1 hr. The parameter used for this work was
maximal rlu, which was generally observed within minutes of
initiating the reactions under the conditions used. For experiments
using N-formyl-Met-Leu-Phe (fMLP), PMN were incubated with
20 mL per well of 2.5 mM fMLP (Sigma) at 37uC for 5 min before
adding opsonized merozoites to start the reaction.
Determination of the standardized ADRB index
The maximal rlu primary data were standardized using the HIS
serum pool as the internal control. Due to relatively rapid maximal
rlu readout, the HIS standard value was determined as the average
of duplicate measurements in the first and last wells of every plate,
although there was generally ,5% difference in the two readings.
Data are presented as a standardized merozoite Antibody
Dependent Respiratory Burst (ADRB) activity index calculated as:
ADRB index~ rlu maximum sample=rlu maximum HIS ðÞ x1000
Only experiments in which the HIS rlu maximum was $100
(.6x background) were included in the analyses. An additional
internal control with the same positive serum was included in
each run.
ELISA
Merozoites resuspended in PBS were lysed with 3 freeze-thaw
cycles, dosed by BCA (Pierce), diluted to 10 mg.mL
-1 in PBS and
coated on MaxiSorp plates (Nunc). The ELISA protocol was
described previously [3,30]. The HIS positive control was titered
on each plate in 2-fold dilutions starting from 1:200 for IgG1 and
IgG3, or from 1:5,000 for total IgG. Samples were analyzed at 3
dilutions, either 1:200, 1:400 and 1:800 for IgG1 and IgG3, or
1:5,000, 1:10,000 and 1:20,000 for total IgG. Arbitrary titers were
extrapolated from the HIS regression curve using a four-
parameter logistic fit. The program (in Excel) constructs a sigmoid
4-parameter curve for the calibrator, by an interactive process.
The unknowns are then calculated by the use of the 4-parameters
estimated. The program can be obtained from Ed Remarque
(remarque@bprc.nl), and is accompanied by a manual with all the
formulae and estimation methods outlined.
Statistical analysis
Antibody levels (ELISA analysis) and ADRB comparisons were
analyzed for statistical significance using the Wilcoxon signed rank
test and the Spearman rank correlation test for non-normally
distributed data. The Mann Whitney test was used to compare
unpaired data, and only P,0.05 was considered significant. A
Poisson regression model was used to analyze the relationship
between the ADRB index and the incidence of clinical episodes
during the following transmission season (5.5 months in 2002) in
Ndiop (mesoendemic), and during the same period in Dielmo
(holoendemic).
Malaria episodes were defined as the presence of fever ($38uC)
and/or malaria-like symptoms with parasitemias higher than a
given threshold value above which an individual had a
significantly higher probability that the observed fever was due
to malaria. Parasitemias were determined using thick smears
where parasites and leucocytes, but not erythrocytes, can be
reliably enumerated by Giemsa staining. Thresholds were
determined statistically and have been used in other studies
carried out in the two villages [3,30]. For Ndiop the threshold was
not age dependent, and was 30 trophozoites / 100 leucocytes
(Christophe Rogier and Andre ´ Spiegel, unpublished data). In
Dielmo symptoms occurred as a function of age-dependent
pyrogenic parasitological thresholds (Rogier et al. (1996) Am J
Trop Med Hyg 54:613), which were the following (per 100
leucocytes): 0–12 months, 245 parasites; 12–23 months, 270
parasites; 2–5 yr, 240 parasites; 5–10 yr, 200 parasites; .10 yr,
155 parasites; .60 yr, 50 parasites. The same thresholds were
used here, and didn’t depend on conditions specific to the study.
When fever persisted to the next day, another thick blood smear
was made. Treatment was given to patients with fever and/or
symptoms compatible with malaria if parasite density was above
the threshold. This protocol and the intensive follow up of the
study insured that febrile episodes were correctly categorized and
that no malaria episodes were missed.
The time at risk for each villager was calculated as the number
of days actually spent in the village during the 5.5-month follow-up
period. Episodes were considered independent if separated by .15
days. Risk for each individual was reduced by 15 days following a
diagnosis of malaria, or by 8–15 days following anti-malarial
treatment regardless of diagnostic criteria, depending on the drug
administered (8, 10, and 15 days for quinine, chloroquine, and
sulfadoxine-pyrimethamine, respectively [37,38]). The times used
in this study are based on data concerning the half-life of the drugs
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respectively 10 hr, 8 days and 4 days [37]. For chloroquine a half-
life of 10–70 hr was used (French notice on drugs and drug
addiction / AFSSAPS; 13 December 2006). The intensive follow-
up used in this study, including random urine tests, allowed us to
determine precisely the beginning and the end of drug treatments
and to eliminate any risk of auto-medication.
The Ndiop analysis included 114 individuals with a total of 121
clinical episodes during the follow-up period. The incidence of
clinical malaria for each individual was calculated as the number
of clinical episodes divided by the number of days at risk during
the 5.5-month follow-up. The mean incidence as a function of age
bracket, defined as the sum of individual incidences divided by the
number of individuals in that age bracket, was: (i) 2–14 years:
0.015, n=49 (ii) 15–29 years: 0.004, n=32 and (iii) $30 years:
0.001, n=33 (P,0.001). The Dielmo analysis included 116
individuals with a total of 50 clinical episodes during the follow-up
period. The mean incidence of clinical malaria as a function of age
bracket was (i) 2–6 years: 0.0188, n=18, (ii) 7–14 years: 0.0018,
n=31 and (iii) $15 years: 0.0003, n=67 (P,0.001). Age
stratification was based on parasitological and clinical data
obtained during a 10-year longitudinal study [3,30,32,33,39].
ADRB index stratification was determined by use of Akaike’s
information criterion (AIC).
Multivariate analyses used the following strategy for model
selection: (i) A model containing all variables with a P value#0.3
was first fitted. (ii) Variables were then excluded according to a
backward elimination procedure. (iii) Variables with dichotomized
P values.0.3 were added to the model, one by one, and any
variable that reduced the deviance significantly was retained in the
model. (iv) Interactions among variables were determined for
inclusion in the final model.
Statistical analyses were performed with Egret (version 3.01;
Cytel) and Statview (version 5.0; SAS Institute) software.
Results
Merozoite preparations
Since merozoites are the key inducers of ADRB activity,
reproducible high throughput chemiluminescence analyses re-
quired access to ample supplies of suitable merozoite material.
Two protocols were investigated for merozoite preparation. (i)
Large quantities of merozoites could be regularly harvested from
post-invasion media of cultures with 5–10% parasitemia by
centrifugation, but the preparations included some contaminating
debris. Figure 1A shows a preparation using this method.
Merozoites are visualized by confocal micrography as dense
particles of 1–2 mm which are labeled by green immunofluores-
cence staining using a rabbit polyclonal antiserum raised to
baculovirus recombinant P. falciparum MSP1p19. The insert at
upper right shows immunofluorescence results using a control
rabbit antiserum raised to insect cells infected with a baculovirus-
null construct expressing no heterologous protein, indicating that
the anti-MSP1p19 staining is highly specific and not due to
possible contaminants present in the immunizing MSP1p19
antigen preparation. Diffuse light staining in Figure 1A is due to
merozoites out of focus in the field shown. This can be seen in
Figure 1B showing two images at a 90u angle of a confocal 3-D
projection indicating that direct visualization of anti-MSP1p19
immunofluorescence staining at left gives a poor representation of
what is actually a dense layer of merozoites that are not all in the
same plane (right). The elongated aspect of the individual
merozoites is an artifact of the confocal imaging technioque. (ii)
Percoll gradient extraction from synchronized cultures of mature
schizonts gave cleaner, more concentrated merozoites, and the
best chemiluminescence (Figure 1C). However, this technique
yielded limited material and damaged cultures, so it was unsuitable
for high throughput. Freezing merozoite pellets, increased ADRB
activity somewhat (Figure 1D), but antibody complexes with
putative cytosolic antigens did not explain the increase, since
merozoite sonication abrogated most ADRB activity (Figure 1D).
Importantly, this result confirmed that opsonized merozoites, even
if permeabilized by freezing, mediate ADRB activity, and was
a key condition for the technical feasibility of the assay. In
all subsequent experiments centrifuged frozen merozoites were
used.
Effector cells
The best PMN preparations regarding both yield and activity
were obtained using a single step ficoll gradient separation
followed by RBC lysis. Donor dependant variability in PMN
activity was minimized by using pools from several donors, and
also allowed more sera to be tested in parallel. PMN from non-
infected European or Senegalese donors were equally reactive with
immune sera from both sites (data not shown). However, the
requirement for fresh PMN and utilization on the day of harvest is
the sine qua non of this assay. In this study PMNs were used as
rapidly as possible after harvest and purification. However, it was
determined subsequently that higher chemiluminescence signals
can be obtained when PMNs remain at room temperature 3–4 hr
after harvest before purification (but not overnight), possibly due to
up-regulation of Fc receptors.
PMN respiratory burst activity depends on merozoites
and immune antibodies
To confirm that PMN respiratory bursts are induced only by
merozoites [26,40], chemiluminescence was measured in the
presence of immune serum using: (i) merozoites, (ii) normal RBC,
(iii) RBC with 5% parasitemia (.80% schizonts and rosettes), (iv)
lysed parasitized RBC (10% parasitemia) or (v) neither merozoites
nor erythrocytes. Figure 2 shows that PMN ADRB activity
depends exclusively on merozoites, and not on possible contam-
inants present in merozoite preparations, including normal or
parasitized RBC, lysed parasitized RBC (containing hemozoin,
food vacuoles, membrane debris etc.), or on immune sera in the
absence of merozoites. Thus, any contaminants in the centrifuged
merozoite preparations as seen in Figure 1A, would not contribute
to chemiluminescence readout. Strong chemiluminescence was
observed only in the presence of PMN, merozoites (fresh or frozen)
and immune sera together. Neither PMN alone, with or without
HIS, nor PMN and merozoites, with or without non-immune sera,
could elicit chemiluminescence above background levels. PMNs
previously activated with fMLP showed increased chemilumines-
cence, indicating that internal positive control values do not
represent the maximal response detected by the system, also
confirmed by S4 results in Figure 2, with ADRB index values
almost twice as high as the HIS controls.
Standardization of chemiluminescence readout
Figure 3 shows chemiluminescence readout as a function of time
from three independent experiments (three different PMN pools)
either without serum (blank), or with NIS or HIS sera pools or
serum from a single immune donor (S1) (Figure 3A-C). NIS alone
showed only background reactivity similar to readouts without
serum. Although the curves are different in the three experiments,
those generated by the S1 sample and the HIS standard in the
same experiment are very similar. In particular, in each case the
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though the absolute values for both are different for each
experiment. Thus, using maximal HIS rlu values as an internal
standard, a reproducible arbitrary unit, the ADRB index, could be
calculated as described in Materials and Methods. ADRB indexes
determined for the S1 sample in the three experiments shown in
Figure 3 were 1183, 1072 and 1126, yielding a mean of 1127+/
25%. Generally, intra-assay reproducibility (1 PMN pool) was
.95 %, while inter-assay reproducibility (different PMN pools)
was .80 %. It is possible that the area under the curves could be
used as the readout rather than maximal rlu, since the curves were
similar within a given experiment (same PMN batch), but this is a
much more complicated measure, likely reflecting more complex
phenomena. The standardization using maximal rlu was another
sine qua non of the experimental approach, allowing data from
different experiments to be compared.
Dependence of chemiluminescence activity on IgG and
complement
To investigate the role of IgG in mediating chemiluminescence
activity, seven sera with high ADRB values were individually
depleted of IgG by passage over Protein-G, and the flow-through
was concentrated to the original volume (IgG depleted serum).
Figure 4 shows that: (i) untreated sera or after complement
inactivation (lanes 1 and 2 respectively) induce statistically similar
chemiluminescence signals using the Wilcoxon signed rank test
(P=0.5), (ii) purified IgG (lane 4) induces chemiluminescence
signals similar to untreated sera (P=0.4) or after complement
inactivation (P=0.6), and (iii) sera depleted of IgG gave negligible
activity (lane 3). These results demonstrated the IgG dependence
of ROS release, and indicated that there was no essential
requirement for complement under the conditions of the ADRB
assay.
Figure 1. Characterization and activity of merozoite preparations. (A) Confocal imaging of a merozoite preparation showing a simple
transmission image superimposed with immuno-fluorescence staining by a 1:500 dilution of rabbit polyclonal anti-baculovirus recombinant
PfMSP1p19 [35], and a 1:1000 dilution of Alexa Fluor 488 conjugated goat anti-rabbit IgG (H+L) (Molecular Probes). The insert at upper right shows
control immuno-fluorescence staining on the same preparation using a 1:500 dilution of rabbit polyclonal anti-[baculovirus-null infected insect cells]
and the Alexa Fluor 488 conjugate. (B) Immuno-fluorescence staining with anti-PfMSP1p19 as in (A) above showing two images from a confocal 3-D
projection, either a direct view perpendicular to the slide (left) or at a 90u angle (right). The images are enlarged 5x compared to (A). (C)
Chemiluminescence using HIS and merozoites prepared from (i) synchronized mature schizont cultures and percoll fractionation (blue trace) or (ii)
centrifuged culture supernatants (orange trace). (D) ADRB indexes determined with a single pool of PMN using fresh (orange), frozen (green) or
sonicated (3650 at 80 watts) (blue) merozoites and immune (HIS, S2, S3, or S4) or non-immune (NIS, S5, S6) sera.
doi:10.1371/journal.pone.0009871.g001
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conditions
ADRB indexes were compared in sera from residents of Ndiop
(114) and Dielmo (116), corresponding to meso- or holo-endemic
settings respectively. The median ADRB index for Dielmo was
significantly higher than for Ndiop (268 and 179 respectively,
P=0.002). This likely reflects higher anti-merozoite antibody
levels due to the prevailing holoendemic conditions.
When ADRB indexes from the Dielmo cohort were compared
between the group of apparently healthy individuals, who
nevertheless had circulating parasites at the time of sampling (58
asymptomatic carriers), and the group without circulating
parasites (58 individuals), an average 36% reduction was observed
in the former (P,0.001, Figure 5). A similar trend was observed in
Ndiop, as indicated by 75 percentile levels (top of bars). However,
since there were only 17 asymptomatic carriers (22%), the data did
not reach statistical significance. These results could be explained
by hypothesizing that parasitemia is being controlled to relatively
low levels in asymptomatic carriers in part by anti-MSP antibodies
which bind to merozoites, reducing the amounts of free anti-MSP
antibodies available to mediate ADRB activity in serum samples
from such individuals.
ADRB activity is correlated with anti-merozoite cytophilic
IgG1 and IgG3 antibody titers
To determine if ADRB activity is associated with particular IgG
isotypes, sera from 88 aparasitemic Ndiop residents were
monitored for merozoite antibodies using isotype specific reagents.
While only 3 or 4 sera were above background for IgG2 and IgG4
respectively (dilution 1:100), all were positive for IgG1 and IgG3.
Arbitrary total IgG, IgG1 and IgG3 titers were calculated for each
serum using the HIS standard regression curve. When ADRB
indexes were plotted against anti-merozoite IgG titers (IgG total,
IgG1 or IgG3), there was a correlation, but the coefficient of
correlation R
2 was very low, ranging from 0.14 to 0.44 and the
linear or log-linear plots weren’t very convincing (data not shown).
For this reason we preferred to consider ADRB versus IgG
associations as a function of the dichotomized ADRB levels, which
were the same in both settings, and which appear to have clinical
relevance (see below). Figure 6 shows that anti-merozoite IgG,
IgG1 and IgG3 titers correlated positively with ADRB indexes
(P,0.001 for all, Mann-Whitney test). To implicate preferentially
IgG1 or IgG3 in ADRB activity, the Spearman test was used to
compare IgG3:IgG1 ratios stratified into three groups: (i) ,0.5 (ii)
$0.5,1 and (iii) $1 with unstratified ADRB indexes. A significant
positive correlation was seen only for sera with an IgG3:IgG1 ratio
of ,0.5 (P=0.002), suggesting there may be a predominate role
for IgG1.
Association between ADRB index and susceptibility to
clinical malaria at a meso-endemic site
Associations were analyzed between ADRB indexes and the
number of cumulative clinical episodes experienced during the
5.5-month 2002 transmission season in Ndiop (meso-endemic).
The definition of malaria episodes, the calculation of individual
time at risk, and the basis of age brackets for malaria susceptibility
in Ndiop are described in Materials and Methods. The best
Poisson regression model according to AIC was obtained using a
cut-off close to the mean ADRB index value (250). A bivariate
analysis showed that the variables significantly associated with the
number of clinical attacks were (i) the continuous ADRB index
([RR]=1.004 per ADRB unit lost, P,0.001), or the dichotomized
ADRB index, (ii) age, and (iii) hemoglobin phenotype (normal vs
AS) (Table 1). Conversely, positive parasitemia at enrolment was
not associated with the number of clinical attacks. Following
multivariate analysis described in Materials and Methods, two
Figure 2. PMN respiratory burst activity depends on merozoites and immune antibodies. ADRB indexes determined as described in
Materials and Methods using a single pool of PMN: with immune (HIS) or non-immune (NIS) sera only (blue); with merozoites and immune (HIS, S2,
S3, or S4) or non-immune (NIS, S5, S6) sera (green) or the same with fMLP activated PMN (yellow); with normal (light red), parasitized (dark red) RBC,
or lysed parasitized RBC (3x freeze-thawed) (grey) in the presence of immune or non-immune sera.
doi:10.1371/journal.pone.0009871.g002
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ing ADRB index (RR=1.002, P=0.049), age (15–29 vs. $30
years, RR
1=3.3; 2–14 vs $30 years, RR
2=12.2; P=0.02 and
P,0.001, respectively), and hemoglobin phenotype, or (ii)
dichotomized ADRB index, age, and hemoglobin phenotype
(Table 1). Hemoglobin phenotype was no longer significant in
either model. ADRB index and age were still significantly
associated with immune status when using the mean ADRB index
cut-off of 250 as shown in Table 1. The second model was the best
(AIC=120.4 vs 120.6) indicating that the risk of malaria attack
was nearly 1.8-fold higher overall for individuals with ADRB
index ,250 than for those with ADRB index $250, after
adjustment for age (P=0.036, Table 1). The impact of ADRB
index dichotomization at 250 with regard to cumulative clinical
episodes, recorded over the 5.5 month follow-up period in
different age groups (inversely related), is shown in Figure 7A.
Within each age group, individuals with a serum ADRB index
$250 before the transmission season had systematically fewer
clinical episodes than those with ADRB index ,250, except at the
end of the transmission season in the 15–29 year group. This
association between ADRB index and morbidity was most striking
for the most susceptible 2–14 year olds.
Anti-merozoite IgG levels and clinical outcome for non-
parasitized Ndiop inhabitants were correlated after bivariate
analysis (P,0.001), but anti-merozoite IgG was no longer
significant when age was included in the Poisson regression
analysis for the multivariate model (P=0.91, Table 2).
Association between ADRB index and susceptibility to
clinical malaria at a holo-endemic site
Similar associations between ADRB index and number of
cumulative clinical episodes, experienced during the same 5.5
month follow-up period in 2002, were analyzed in Dielmo (holo-
endemic). Analyses were carried out as described above for Ndiop.
As for Ndiop, a bivariate analysis showed that the variables
significantly associated with the number of clinical attacks were (i)
the continuous and dichotomized ADRB index (continuous rate
ratio [RR]=1.001 per unit lost; dichotomized rate ratio at 300
(mean value) RR=30.6; dichotomized rate ratio at 250 (Ndiop
model value) RR=11.8; P,0.001 for all), and (ii) age (values in
Table 3). Conversely, hemoglobin phenotype and positive
parasitemia at enrolment were not associated with the number
of clinical attacks, although hemoglobin phenotype had a
significant effect in some multivariate models. After multivariate
analysis, three alternative models were proposed using: (i)
continuously decreasing ADRB index (RR=1.005, P=0.006)
and age (7–14 vs. $15 years RR
1=4.2; 2–6 vs. $15 years
RR
2=31.9; P=0.032 and P,0.001 respectively), (ii) ADRB index
dichotomized at 300 units (,300 vs $300, RR=12.2, P=0.014),
and age (7–14 vs. $15 years RR
1=3.8; 2–6 vs. $15 years
RR
2=41.1; P=0.046 and P,0.001 respectively) and (iii) ADRB
index dichotomized at 250 units, age, and hemoglobin phenotype
(Table 3). ADRB index and age were still significantly associated
with immune status for each model. The third model (Table 3),
using the same cut-off ADRB value of 250 as for Ndiop, was the
best (AIC=90.7 vs 113.6 and 108.6). In this model hemoglobin
phenotype was not significant, but statistically important (score test
Hb: P=0.035). Strikingly, the model predicts that in this holo-
endemic setting the risk of malaria attack is over 17-fold higher for
individuals with an ADRB index ,250 compared to those with an
ADRB index $250 after adjustment for age, equivalent to a 94%
reduction of clinical episodes (P=0.006). As above, the impact of
functional antibodies in the ADRB assay with regard to
cumulative episodes in different age groups is shown in
Figure 7B. Again, regardless of age group, individuals with a
serum ADRB index $250 had systematically fewer clinical
episodes than those with ADRB index ,250, especially in the
younger, most susceptible age groups. The use of different scales of
malaria incidence in Figure 7 is a reflection of both different
transmission rates and age dependent susceptibility.
Discussion
Recent years have seen significantly increased attention focused
on the search for malaria vaccines offering broad, long-lasting
protection. Many vaccine candidates have been proposed, but the
high cost of clinical testing has underscored a need for
prioritization, and led to persistent calls for development of in
vitro functional tests correlated with immune protection in humans.
The latter parameter implies either monitoring infection after
deliberate challenge, which is ethically controversial for blood
stage candidates, or longitudinal monitoring of clinical episodes in
endemic populations. In both cases ‘‘correlates’’ implies large
enough sampling to ensure statistical relevance. Some studies have
correlated specific antibody levels with clinical protection [2–5],
but not functional attributes of these antibodies. Conversely, while
Figure 4. Serum IgG, but not complement, mediates ADRB
activity. ADRB indexes were determined individually using 7 different
immune sera either untreated (lane 1), after inactivation of complement
(lane 2), after IgG depletion (lane 3), or after purification of IgG (lane 4).
Distribution and median values are indicated by vertical and horizontal
lines respectively.
doi:10.1371/journal.pone.0009871.g004
Figure 3. ADRB chemiluminescence profiles can be standardized. (A-C) Chemiluminescence profiles from 3 different ADRB experiments (3
PMN pools) tested without serum (blank, green trace), or in the presence of NIS (grey trace), HIS (red trace) and the same individual sample serum (S1,
blue trace). The ADRB index for S1, calculated as described in Materials and Methods using HIS as a positive internal standard, is shown for each
experiment.
doi:10.1371/journal.pone.0009871.g003
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9871Figure 6. Chemiluminescence activity correlates with anti-merozoite IgG1 and IgG3 isotype titers. Sera from 88 aparasitemic Ndiop
residents were stratified into 2 groups with ADRB indexes ,250 (blue, 59 sera) or ADRB $250 (red, 29 sera). Stratified ADRB indexes are shown as a
function of (A) total anti-merozoite IgG titer (1:5000 dilution), and (B) separate anti-merozoite IgG1 and IgG3 titers (1:200 dilution for both).
Statistically significant differences, as detected with the Mann-Whitney test, are indicated.
doi:10.1371/journal.pone.0009871.g006
Figure 5. Comparison of ADRB index profiles for Dielmo and Ndiop. ADRB index values for Dielmo and Ndiop were analyzed as a function of
parasite carriage at the time of sampling. Statistical significance was determined using the Mann-Whitney test and significant P values are noted.
doi:10.1371/journal.pone.0009871.g005
Malaria, Merozoites, Abs, PMN
PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9871ADRB functional IgG activity was highly correlated with clinical
outcome here (especially for Dielmo and for the youngest children
in Ndiop), anti-merozoite IgG levels (ELISA) were not when age
was also considered, showing that ADRB functionality was a more
relevant predictor of clinical outcome.
These results constitute the first clear demonstration of a
functional antibody immune correlate of protection against P.
falciparum malaria pathology in humans in two different transmis-
sion settings. The approach used relied on two essential elements:
(i) development of a reproducible standardized, high-throughput
assay quantifying antibody dependent respiratory burst (ADRB)
activity by PMN, and (ii) access to anti-sera from a large cohort of
endemic donors participating in a cross sectional prospective study
with intensive clinical follow-up. The standardized protocol
permitted inter-experimental comparisons, thereby increasing
the statistical power to investigate associations between the
functional activity of antibodies induced by natural exposure and
clinical protection. Extensive epidemiological data have been
collected for more than 15 years from Ndiop and Dielmo with
seasonal or year round transmission respectively. Data from both
Table 1. Poisson regression analysis of ADRB index values and clinical outcome for Ndiop.
NDIOP Bivariate analysis Multivariate model
Category Subcategory RR 95%CI P RR 95%CI P
ADRB $250 11
,250 3.673 2.171–6.215 ,0.001 1.789 1.038–3.077 0.036
Age (years) $30 11 (,0.001)
15–29 3.632 1.349–9.783 0.01 3.203 1.182–8.681 0.022
2–14 15.925 6.484–39.116 ,0.001 12.627 5.036–31.660 ,0.001
Hemoglobin phenotype AA 1
AS 3.310 1.616–6.780 0.001 NS
Deviance 118.4
AIC 120.4
Bivariate and multivariate Poisson regression models were built to analyze the relation between ADRB and acute malaria morbidity. The bivariate model includes
morbidity and analysis of one variable. The multivariate model includes morbidity and other variables such as age and dichotomized ADRB index (above and below the
mean ADRB value of 250), where the impact of the different variables is analyzed together. The P value in parenthesis refers to the overall impact of age on the
multivariate model. (NS: non significant.)
doi:10.1371/journal.pone.0009871.t001
Figure 7. Dichotomized ADRB indexes have an age-dependent impact on clinical episodes at both low and high transmission sites.
Analyses of associations between ADRB index and the number of clinical episodes experienced during a 5.5-month follow-up period, gave the best
Poisson regression model with a cut-off of 250. The cumulative mean no. of clinical episodes/person/day at monthly intervals across the follow-up
period were plotted for different age groups as a function of ADRB index ,250 (blue trace) or $250 (red trace). (A) Ndiop: age groups: ,15 years, 15–
29 years, and $30 years (Table 1); (B) Dielmo: age groups: ,7 years, 7–14 years, $15 years (Table 3).
doi:10.1371/journal.pone.0009871.g007
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model, and showed that donors with serum ADRB indices $250,
had significantly fewer clinical malaria episodes than those with
ADRB ,250, translating into a striking 17-fold risk factor
associated with this parameter in Dielmo, and a 1.8-fold risk
factor in Ndiop. The difference in risk factors between the two sites
has both statistical and physiological explanations. Statistically it is
linked to the fact that in Dielmo, only 22 of 116 villagers
experienced one or more malaria episodes, whereas in Ndiop there
were 3 times as many having clinical accesses (63/114). But 20 of
the 22 Dielmo villagers with malaria had an ADRB index , 250,
compared to 51 of 63 in Ndiop, explaining both the stronger RR
value and the larger confidence interval in the former. On a
physiological level it is notable that Dielmo has an infection
pressure (number of infectious bites) over 10 times stronger than
Ndiop, although Dielmo villagers have 2–3 fold fewer episodes.
Thus factors related to clinical protection are more intensively
‘‘boosted’’ in Dielmo resulting in much stronger associations.
It is notable here that the clinically relevant dichotomized value
of 250 for ADRB index was independently found to be the same in
both villages in spite of the very different transmission character-
istics. In addition the 250 value was the mean ADRB index in
Ndiop and close to the mean (300) in Dielmo. Thus, there may be
a ‘‘threshold’’ ADRB response important for clinical protection,
even if the precise biological phenomena it reflects are not clear.
Taken at face value, these results suggest, but do not prove, that
extra-cellular ROS release induced in PMNs by opsonized
merozoites, may be a key effector function for protection against
blood stage P. falciparum infection, despite the lack of prominence
of either PMN or ROS in many reviews on the subject, if they are
mentioned at all [20,21]. Several observations are consistent with
this hypothesis. (i) PMNs have generally shown the most intense
respiratory burst activity when stimulated by P. falciparum asexual
blood stage parasites, particularly merozoites [12,27,41] and
PMN growth inhibition of P. falciparum in vitro was substantially
dependent on antibody opsonins in immune serum [42]. (ii) The
isoluminol reagent used here detects specifically extra-cellular
ROS metabolites [23], which are known to be particularly toxic
for intra-erythrocytic parasites [17,18,19]. ROS could be a more
effective agent targeting this form of the parasite than specific
antibodies, given the extreme polymorphism of parasite antigens
on the surface of the infected red cell. (iii) ADRB activity
apparently did not require prior PMN activation, since freshly
harvested cells from normal donors released ROS instantaneously
Table 3. Poisson regression analysis of ADRB index values and clinical outcome for Dielmo.
DIELMO Bivariate analysis Multivariate model
Category Subcategory RR 95%CI P RR 95%CI P
ADRB $250 11
,250 11.762 4.669–29.631 ,0.001 17.509 2.275–134.744 0.006
Age (years) $15 11 (,0.001)
7–14 8.426 2.595–27.362 ,0.001 2.876 0.759–10.904 NS
2–6 87.542 31.244–245.282 ,0.001 17.637 5.042–61.690 ,0.001
Hemoglobin phenotype AA 1
AS 0.79 0.291–2.141 NS
Scoretest Hb NS 0.035
Deviance 86.7
AIC 90.7
Bivariate and multivariate Poisson regression models were built to analyze the relation between ADRB and acute malaria morbidity. The bivariate model includes
morbidity and analysis of one variable. The multivariate model includes morbidity and other variables such as age, ADRB index dichotomized at 250, and hemoglobin
phenotype, where the impact of the different variables is analyzed together. The P value in parenthesis refers to the overall impact of age on the multivariate model.
(NS: non significant.).
doi:10.1371/journal.pone.0009871.t003
Table 2. Poisson regression analysis of anti-merozoite IgG levels and clinical outcome for non-parasitized Ndiop inhabitants.
NDIOP Bivariate analysis Multivariate model
Category Subcategory RR 95%CI P RR 95%CI P
anti-merozoite IgG level (continous) 0.999 0.9985–0.9995 ,0.001 1.000 0.9996–1.0004 NS
Age (years) $30 11 (,0.001)
15–29 3.632 1.349–9.783 0.01 2.446 0.822–7.271 NS
2–14 15.925 6.484–39.116 ,0.001 16.432 5.954–45.350 ,0.001
Deviance 87.8
AIC 89.8
Bivariate and multivariate Poisson regression models were built to analyze the relation between anti-merozoite IgG levels and acute malaria morbidity. The bivariate
model includes morbidity and analysis of one variable. The multivariate model includes morbidity and other variables such as age and IgG levels, where the impact of
the different variables is analyzed together. The P value in parenthesis refers to the overall impact of age on the multivariate model. (NS: non significant.)
doi:10.1371/journal.pone.0009871.t002
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ing PMNs would be rapidly responsive to the presence of this
stimulus in vivo. (iv) Neutrophils represent 50–75% of blood
leucocytes, and undergo very characteristic changes in patients
infected with P. falciparum (or P. vivax) [43], where neutropenia is
frequent and neutrophil populations often shift towards more
immature forms. (v) ROS mediated killing of intra-erythrocytic
parasites could explain the observation that concurrent infections
by P. falciparum and P. vivax are mutually suppressive [44], since
PMN generation of ROS, induced by opsonized merozoites of
either species, would be equally effective against intracellular
parasites of both species. Nevertheless, a correlation between
children with severe malarial anemia and enhanced innate
production of ROS by granulocytes, is indicative of a possible
negative effect of ROS on the host [45].
The similarities of the ADRB and ADCI assays suggest that they
may actually reflect the same phenomena. The short half-life of
PMNs compared to monocytes, could explain why the former did
not appear to be functional during the long 24–96 hr culture
periods required for the ADCI assay [12,46]. Notably, we
observed a rapid decline in the capacity of freshly harvested
PMNs to generate ROS, even over the short 60 min duration of
the ADRB assay. Since activated monocytes (and macrophages)
also release ROS, this could be the unidentified soluble factor
mediating ADCI activity. In addition, the prolonged in vitro ADCI
assay conditions are likely to transform and activate monocytes in
ways not relevant to their in vivo function as a relatively small
inactive pool of macrophage precursors in the blood. Singlet
oxygen may preferentially mediate ROS growth inhibition of P.
falciparum, explaining the inability of superoxide dismutase and
catalase to block ADCI activity [12,46].
Several important questions regarding the molecular basis of
ADRB activity remain to be answered. (i) It was dependent on
serum IgG1 and IgG3 isotypes, which mediate antibody
interactions with accessory cells via Fcc receptors, and are
associated with clinical protection against malaria [47,48].
Cross-linking of high affinity FccRI triggers PMN respiratory
bursts, but FccRI expression is inducible in PMNs, and could be
up-regulated by cytokines such as TNFa, IFNc and TNFb, which
increase antibody-dependent chemiluminescence signals [26].
Although the PMN were from healthy donors and used within
hours of harvest, we do not know what Fcc receptors were
expressed. Nevertheless, the primary limitation of the ADRB assay
is linked to the characteristic fragility of PMNs, which have a very
short half-life in vivo (around 7 hr when circulating). (ii) The ADRB
assay requires antibodies compatible with human Fcc receptors, so
those induced by vaccination of animals may not be functional.
Although antibodies to P. falciparum MSPs induced in rabbits were
not functional, those raised in at least some primate species may be
compatible. (iii) Since the toxicity of ROS generated by PMN is
postulated to be an important factor in ADRB association with
protection, the inhibitory effects of ADRB assay supernatants on P.
falciparum cultures should be evaluated, and the putative
implication of particular ROS determined using reversible
inhibitors such as histidine, tryptophan, superoxide dismutase
and/or catalase, to indicate which oxygen radicals, if any, are
involved [49]. (iv) ROS release has often been considered to be
primarily a reflection of PMN phagocytosis of opsonized
merozoites, but quantitative links between the two processes are
not clear. The use of a flow cytometric phagocytosis assay in
association with ADRB readouts could help to establish a clearer
relationship [50]. Further work should attempt to address the
issues outlined here.
In related work, the ADRB assay was used to evaluate the
functionality of antibodies in human immune sera specific for
baculovirus PfMSP1p19, PfMSP4p20 and PfMSP5 vaccine
candidates, and has provided strong arguments for the vaccine
candidacy of some of these antigens (manuscript in preparation). If
reproducible in other laboratories, the ADRB assay could prove to
be an important new tool for evaluating the functional relevance of
merozoite specific antibodies induced either by natural infection or
vaccination with recombinant merozoite vaccine candidates
[8,29–31].
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